References of "Tumori"
     in
Bookmark and Share    
Peer Reviewed
See detailThe Potent Angioinhibin Agm-1470 Stimulates Normal but Not Human Tumoral Lymphocytes
Antoine, Nadine ULg; Daukandt, M.; Locigno, R. et al

in Tumori (1996), 82(1, Jan-Feb), 27-30

BACKGROUND: AGM-1470 is a newly synthesized molecule developed as an analog of the potent anti-angiogenic fumagillin. Its efficacy in restraining tumor growth in vivo and the absence of major side effects ... [more ▼]

BACKGROUND: AGM-1470 is a newly synthesized molecule developed as an analog of the potent anti-angiogenic fumagillin. Its efficacy in restraining tumor growth in vivo and the absence of major side effects have already led to phase I clinical trials in patients with solid cancers. However, neither the exact mechanisms of action of AGM-1470 nor its effects on the host of normal cells have been extensively studied. Recently, we showed that AGM-1470 enhanced the proliferation of B lymphocytes in the presence of T cells. Since AGM-1470 could potentially be used in patients with lymphoma, it was urgent to test the effect of the molecule on the proliferation of tumor lymphocytes. METHODS: The possible effect of AGM-1470 on the proliferation of normal or tumor lymphocytes was evaluated by thymidine-incorporated assays. Normal T and B lymphocytes were purified from human tonsils. The tumor lymphocytes used in the study were Molt 3, Molt 4 and Jurkatt cell lines for the T lineage and Daudi and Radji cell lines for the B lineage. RESULTS: As shown previously, AGM-1470 stimulates the proliferation of normal B lymphocytes through an action on normal T cells. THe angioinhibin was ineffective ont eh proliferation of both T and B transformed cells. Moreover, in the presence of the drug, tumor T cells co-cultured with normal B lymphocytes did not induce any increase in B cell proliferation, as previously observed with normal T lymphocytes. Inversely, tumor B cells co-cultured with normal T lymphocytes were insensitive to the drug. CONCLUSIONS: Our results demonstrate that AGM-1470 is ineffective on lymphoid tumor cell proliferation and could potentially be safely administered to lymphoma patients. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailRecent advances in prostate cancer metastasis
Waltregny, David ULg; Castronovo, Vincenzo ULg

in Tumori (1996), 82(3, May-Jun), 193-204

Prostate cancer in men has now surpassed lung cancer as the most frequent non-cutaneous cancer. From a biological perspective, prostate carcinoma is unique among human malignancies in the wide discrepancy ... [more ▼]

Prostate cancer in men has now surpassed lung cancer as the most frequent non-cutaneous cancer. From a biological perspective, prostate carcinoma is unique among human malignancies in the wide discrepancy that exists between the prevalence of 'latent' cancer, recognizable only histologically, and that of the clinical disease. Histologically detected localized prostate cancers are heterogeneous, with only a small subset having undergone all of the malignant changes required to produce clinically aggressive tumors. Most of these 'latent' carcinoma never become fully malignant and do not threaten the life or well-being of the host. At present, it is not possible to predict which localized cancers will progress to clinically overt disease. Likewise, many patients have underevaluated and unpredictable extent of their prostate carcinoma, thus resulting in inadequate therapeutic strategies. It is clear that we need to identify molecular and/or cellular markers that are able to define the invasive and metastatic potential of prostate cancer on an individual patient basis. Acquisition of metastatic ability is a definitive criterion by which substage localized prostate cancers. Under the light of recent studies designed to identify some of the features associated with the metastatic phenotype of prostate cancer, the authors review recent advances aimed at gaining insight into those factors that may be involved in prostate cancer metastasis. [less ▲]

Detailed reference viewed: 18 (2 ULg)